Atracurium besylate - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for atracurium besylate and what is the scope of freedom to operate?

Atracurium besylate is the generic ingredient in four branded drugs marketed by Baxter Hlthcare, Baxter Hlthcare Corp, Eugia Pharma, Hikma, Hospira, Hospira Inc, Meitheal, Norvium Bioscience, Teva Parenteral, Watson Pharms Teva, and Watson Labs Inc, and is included in twenty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for atracurium besylate. Three suppliers are listed for this compound.

Summary for atracurium besylate

US Patents:	0
Tradenames:	4
Applicants:	11
NDAs:	23
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	14
Patent Applications:	1,128
What excipients (inactive ingredients) are in atracurium besylate?	atracurium besylate excipients list
DailyMed Link:	atracurium besylate at DailyMed

Recent Clinical Trials for atracurium besylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	N/A
Theodor Bilharz Research Institute	Phase 4
Cairo University	Phase 4

See all atracurium besylate clinical trials

Pharmacology for atracurium besylate

Drug Class	Nondepolarizing Neuromuscular Blocker
Physiological Effect	Neuromuscular Nondepolarizing Blockade

Medical Subject Heading (MeSH) Categories for atracurium besylate

Neuromuscular Nondepolarizing Agents
Nicotinic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for atracurium besylate

M03AC	Other quaternary ammonium compounds
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

US Patents and Regulatory Information for atracurium besylate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Parenteral	ATRACURIUM BESYLATE	atracurium besylate	INJECTABLE;INJECTION	074784-001	Jun 11, 1997		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Norvium Bioscience	ATRACURIUM BESYLATE	atracurium besylate	INJECTABLE;INJECTION	206096-001	Jun 22, 2017		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Hospira	ATRACURIUM BESYLATE	atracurium besylate	INJECTABLE;INJECTION	074740-001	Mar 28, 1997		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for atracurium besylate

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hospira	TRACRIUM PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	018831-001	Nov 23, 1983	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.